Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancerJune 5, 2023Gynecologic CancerImmunotherapyImmuno-oncologyPatient & Survivor Care
Up-front pembro plus chemo boost survival in cervical cancerJune 4, 2023Gynecologic CancerImmunotherapyImmuno-oncologyPatient & Survivor Care
‘Huge step forward’ in advanced ovarian cancerJune 4, 2023Gynecologic CancerImmunotherapyImmuno-oncologyPatient & Survivor Care
‘Exciting’ results for cancer vaccine plus pembro in melanomaApril 21, 2023MelanomaPreventive CarePatient & Survivor CareImmunotherapyImmuno-oncology
AFib risk with cancer drugs underestimatedApril 12, 2023Breast CancerLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersImmuno-oncology
Study gives new insight into timing of combo treatment in metastatic NSCLCApril 10, 2023Lung CancerCNS/Brain CancerImmunotherapyImmuno-oncologyPatient & Survivor CareNeuro-oncology
Adverse events linked to better survival with ICIs in melanomaDecember 30, 2022MelanomaImmuno-oncologyImmunotherapy
Discontinuing immunotherapy: Is the infusion bag half empty or half full?November 23, 2022Lung CancerCNS/Brain CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHead & Neck/Thyroid CancersImmuno-oncology
Acetaminophen linked to diminished response to immunotherapy in cancerJune 8, 2022Patient & Survivor CareImmunotherapyImmuno-oncology
Age, skin cancer risks for ICI-induced bullous pemphigoid identifiedApril 22, 2022MelanomaPatient & Survivor CareImmuno-oncologyImmunotherapy
New injectable gel can deliver immune cells directly to cancer tumorsApril 15, 2022ImmunotherapyImmuno-oncologyRenal Cell Carcinoma
CAR-T in children branching out to solid tumorsMarch 4, 2021Immuno-oncologyPediatricsCNS/Brain CancerNeuro-oncology
FDA approves new indications for pembrolizumabJuly 1, 2020Patient & Survivor CareBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
